VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCC

Michael L. Blute, MD
Published: Thursday, Sep 01, 2016


Michael L. Blute, MD, chair of the Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).

It is important to identify the appropriate criteria for which patients can undergo nephrectomy or kidney-sparing surgery for their disease, Blute explains. However, until more information is available, treatments will need to be individualized based on a patient's comorbidities, age, and current kidney function to inform practitioners which procedure would be more beneficial for patients.

There has been a paradigm shift that urologists are facing in order to avoid chronic kidney disease in patients, he adds. The rates of partial nephrectomy for small renal masses, for example, have been doubled.

Michael L. Blute, MD, chair of the Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).

It is important to identify the appropriate criteria for which patients can undergo nephrectomy or kidney-sparing surgery for their disease, Blute explains. However, until more information is available, treatments will need to be individualized based on a patient's comorbidities, age, and current kidney function to inform practitioners which procedure would be more beneficial for patients.

There has been a paradigm shift that urologists are facing in order to avoid chronic kidney disease in patients, he adds. The rates of partial nephrectomy for small renal masses, for example, have been doubled.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x